1. SAT0190 Reduction of serum immunoglobulin free light chains upon rituximab (anti-CD20) treatment correlates with decreased disease activity in patients with primary sjögren's syndrome. (23rd January 2014) Authors: Bruining, D.M.; Pollard, R.P.E.; Moerman, R.; Meiners, P.M.; Meijer, J.M.; Burgerhof, H.J.; Vissink, A.; Kroese, F.G.M.; Bootsma, H. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 535 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗